Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.54 |
| ▸ | CNR1 | P21554 | 4/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | BAD | Q92934 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15999011 | 0.92 | CNR2 (0.56) | CNR2CNR1MCL1BADALDH1A1 | |
| SCHEMBL15999013 | 0.91 | CNR2 (0.52) | CNR2CNR1MCL1BADALDH1A1 | |
| SCHEMBL1586499 | 0.90 | CNR2 (0.46) | CNR2CNR1MCL1BADALDH1A1 | |
| SCHEMBL2038160 | 0.87 | CNR2 (0.53) | CNR2CNR1MAPTTSHRL3MBTL1 | |
| SCHEMBL1586449 | 0.84 | MAPT (0.59) | MCL1BADALDH1A1MAPTTSHR | |
| SCHEMBL1587303 | 0.83 | MAPT (0.60) | MCL1BADALDH1A1MAPTTSHR | |
| SCHEMBL31133362 | 0.82 | MCL1 (0.47) | CNR2MCL1BADALDH1A1MAPT | |
| SCHEMBL21818692 | 0.82 | MCL1 (0.47) | CNR2MCL1BADALDH1A1MAPT | |
| SCHEMBL2034023 | 0.82 | NPSR1 (0.57) | CNR2CNR1ALDH1A1TSHRNPSR1 | |
| SCHEMBL6042188 | 0.81 | CNR2 (0.70) | CNR2CNR1ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772484-B1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-06-28 | — | — | EP | disclosed |
| CN-103917524-B | Bicyclic heterocycles | ASTELLAS PHARMA INC. (JP) | 2016-05-04 | — | — | CN | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2772484-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| CN-103917524-A | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC | 2014-07-09 | — | — | CN | disclosed |
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | HSD11B1, HSD17B11, HSD17B1 | CNR2 625/4885CNR1 453/4885MCL1 3714/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | CNR2 135/4885CNR1 149/4885MCL1 4211/4885 |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | CNR2 113/4885CNR1 160/4885MCL1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.